P&T Committee

The Pharmacy and Therapeutics (P&T) Committee provides recommendations for the Medicaid Preferred Drug List (PDL). The Committee is composed of Physicians & Pharmacists who meet at least quarterly to consider PDL implementation. These meetings are generally scheduled on the third Thursday of every month at 7:15 A.M. in the Cannon Health Building at 288 N. 1460 W. in Salt Lake City, UT. The P&T Committee reserves the right to adjust the meeting schedule as necessary. Notices for exact meeting times and locations will be published in the Legal Notices sections of the Salt Lake Newspapers at least 24 hours in advance.

The meetings are open to the public. To receive public notice for this meeting by email please sign up on the Utah Public Notice website.

Public Comments for the P&T Committee:

Public comment that responds to the materials presented by the Pharmacotherapy Outcomes Research Center at the Universityof Utah is most helpful. The foundation documents used for most reviews are prepared by the Oregon Evidence-Based Practice Center or the Pharmacotherapy Outcomes Research Center and are posted in advance on the P&T Committee website

Manufacturers are requested to submit any additional materials they would like reviewed as part of the process to:

Gary M. Oderda, Pharm.D., M.P.H
Professor and Director
Pharmacotherapy Outcomes Research Center
University of Utah College of Pharmacy
30 South 2000 East Room 4922
Salt Lake City, UT 84112

All materials must be clearly labeled that they are submitted for consideration as part of the State of Utah Medicaid Preferred Drug List Program review process. Materials must be received at least 60 days before the scheduled review date. Materials most useful to support the evidence-based process include any new evidence (information from clinical trials or studies when possible) after the Oregon monograph was prepared, unpublished materials the company would like considered as part of the process, or any other materials not likely to be included in a literature search.

Persons who wish to address the P&T Committee may contact Utah Medicaid by email, at medicaidpharmacy@utah.gov at least 7 calendar days prior to the meeting. Comments from visitors, while welcome, may be limited due to time constraints

Listed below is a P&T Committee class review tentative schedule:

P&T Tentative Schedule:
February 2016: Skeletal Muscle Relaxants
March 2016: Long Acting Opioids
April 2016: Targeted Immune Modulators
May 2016: HIV - Non-Nucleoside Reverse Transcriptase Inhibitors and HIV - Nucleoside Reverse Transcriptase Inhibitors
June 2016: No Meeting planned
July 2016: HIV – Integrase Inhibitors and HIV - Fusion Inhibitors
August 2016: Antineoplastic Antibiotics
September 2016: Antimetabolite Agents (Antifolate agents, Purine analogs, Pyrimidine analogs)
October 2016: Monoclonal Antibodies (Antineoplastic)
November 2016: DNA Demethylation Agents and DNA Topoisomerase Inhibitors
December 2016: Histone Deacetylase Inhibitors and Platinum Coordination Complex

Listed below are meeting minutes, recordings, agendas, criteria review documents, and reports regarding the P&T Committee. Clinical evidence documents prepared for the P&T Committee meetings will be kept on this website for 6 months.

Meeting recordings will be available online for 1 year. For historical meeting recordings please contact us at medicaidpharmacy@utah.gov.

Current Criteria Review Documents available include:
February 2015: No Meeting
March 2015: Thiazide Diuretic Agents AND Loop Diuretics AND Potassium-Sparing Diuretics
April 2015: Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors
May 2015: Antianginal Agents
June 2015: No Meeting
July 2015: Hepatitis C Combination Agents
August 2015: HIV Protease Inhibitors
September 2015: Bowel Cleansing Agents AND Agents Indicated in the Treatment of Irritable Bowel Syndrome
October 2015: Immune Globulin Agents
November 2015: Ophthalmic Beta-Blockers AND Ophthalmic Cholinergic Agonists
December 2015: Agents for Opioid Induced Constipation
January 2016: Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Inhibitors

The documents are provided as Portable Document Format (PDF) files. If you cannot view a file, please download the free reader from the link below.

Get Adobe Acrobat Reader

Name Type
Parent Directory